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ECONOMIC AND OUTCOMES ISSUES IN
MENTAL HEALTH AND NEUROLOGIC
DISORDERS
"HBI
TREATMENT CHOICE AND THE INCIDENCE
AND ECONOMIC INTENSITY OF HOSPITAL
INPATIENT USE BY DEPRESSED PATIENTS
Croghan TW, Kniesner Tjj, Melfi CA, Klein EG
Eli Lilly and Company, Indianapolis, IN, USA
The purpose of this study was to identify differences in
hospitalization incidence and associated economic impact
by depressed patients initially treated with a selective se-
rotonin reuptake inhibitor (SSRI) versus those treated
with tricyclic antidepressants (TCA).
METHOD: A three-step regression analysis was con-
ducted utilizing data from Marketscana. First, discrete
outcome regression methods were used to test for a sys-
tematic relation between patient characteristics and ini-
tial antidepressant that may be a common factor, with
hospital use forming the basis of an adjustment for a non-
random drug assignment when studying hospital use. The
second step was a discrete outcome regression for
whether a depressed patient is hospitalized. The final step
was a semi-logarithmic regression of hospital expendi-
tures for admitted patients.
RESULTS: The only control independent variable that
mattered to depression-related hospitalizations was prior
admissions. The number of pre-study comorbid condi-
tions was the only significant predictor of drug use. Peo-
ple with more pre-study comorbidities were less likely to
have an initial prescription for fluoxetine (t = 3.33, P <
0.05). Applying statistical correction for this variable, the
estimated relative likelihood of hospitalization with flu-
oxetine versus TCA was 0.47 (95% CI = 0.23-0.93)
(t = 2.22, P < 0.05). The estimated hospitalization rates
for sertraline and TCA were the same (b = 0.81, t =
0.54, P = 0.59). There was no differential effect of spe-
cific anti-depressant on resource use for patients once
hospitalized.
CONCLUSIONS: Patients initially prescribed sertraline
have the same likelihood of hospitalization for a mental
health problem as patients prescribed a TCA. Patients ini-
tially prescribed fluoxetine are half as likely to be hospi-
talized as patients initially prescribed TCAs.
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MEDICAL COSTS OF VENLAFAXINE VERSUS
TRICYCLIC OR TETRACYCLIC
ANTIDEPRESSANT THERAPY AFTER
SWITCHING FROM SELECTIVE SEROTONIN
REUPTAKE INHIBITORS
Griffiths RI, Sullivan EM, Frank RG, Herbert Rj, Strauss Mj,
Goldman HH
Covance Health Economics and Outcomes Services Inc.,
Washington, DC USA
Although selective serotonin reuptake inhibitors (SSRIs)
are often the therapeutic class of choice for depression,
20-50% of patients may be resistant or achieve only par-
tial response. Therefore, clinicians often need to prescribe
alternative therapies.
OBJECTIVE: We compared patterns of medical resource
use and one-year costs in a cohort of patients receiving
venlafaxine versus tricyclic or tetracyclic (TCA) therapy
for depression after switching from SSRI therapy.
METHODS: Using claims data from a managed care orga-
nization, we identified patients diagnosed with depression
who received second-line antidepressant therapy between
1993 and 1997. Second-line therapy was defined as a
switch from SSRI therapy to either venlafaxine or TCA
therapy. Patients with psychiatric comorbidities were ex-
cluded. We compared one-year medical expenditures using
pairwise bivariate and multivariate statistical analysis.
RESULTS: Median total one-year expenditures were
$3,356 for venlafaxine (n = 188) versus $4,661 for TCA
(n = 172) patients. Antidepressant expenditures were
higher for venlafaxine (median = $661) than for TCA
therapy (median = $158). However, this difference was
offset by lower facility expenses ($159 venlafaxine versus
$527 TCA) and by lower professional expenses ($1,410
venlafaxine versus $2,016 TCA). Multivariate analyses
adjusting for age, gender, prescriber of second-line ther-
apy, medication possession ratio, health plan, and six-
month prior comorbidity expenditures showed that total
one-year expenditures were lower among venlafaxine pa-
tients compared to TCA patients (-$313, p > 0.10).
CONCLUSIONS: One-year medical expenditures are
similar among depression patients receiving venlafaxine
versus TCA therapy after switching from SSRI therapy.
Higher antidepressant expenditures in the venlafaxine pa-
tients were offset by lower professional and facility costs.
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COST-EFFECTIVENESS EVALUATION OF NEW
ANTIPSYCHOTICS
Launois R', Knapp M2, Graf v.n. Schulenburg M3, Toumi M4
'Paris North University, Paris, France;-London School of
Economics, London, UK; 3Universitat Hannover, Hannover,
Germany; "Lundbeck, Denmark
New compounds have been introduced to treat schizo-
phrenic patients in the last 4 years. Their safety and effi-
cacy with respect to conventional treatments are well
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documented, but their economic impact in a naturalistic
context is still pending.
OBJECTIVE: The purpose of the study is to evaluate new
antipsychotics in usual practice with a pragmatic Markov
Model of patients compliance under treatment.
METHODS: The model is based on a 6-month Markov
cycle tree divided into four sub-trees: M1, M2, M3, and
M4. (1) M1 identifies the drug strategies in schizophre-
nia: sertindole versus olanzapine versus haloperidol. (2)
M2 enumerates the care structures. Five care manage-
ment categories are defined in function of the place where
patients live (hospital, residential, or private home) and
the intensity of care (intensive or mild residential care, in-
tensive or mild own-home personal care). Care manage-
ment depends on the clinical status (relapse and non-
relapse). Long stay hospitalisation is integrated as a sepa-
rate branch. (3) M3 identifies the clinical events. Each of
the treatments has side effects determining the compli-
ance or noncompliance and the frequency of relapses.
Adverse events are extrapyramidal symptoms, somno-
lence, weight gain, and sexual disturbance. Toxicity rates
are estimated from three integrated summaries of safety.
Compliance and relapse rates are obtained by a meta-
analysis of the literature. They are differentiated accord-
ing to the patients' settings. (4) M4 shows the patients'
paths in the health care system. The corresponding transi-
tional probabilities are derived from two French cohorts
(2,747 pts), a German cohort (459 pts), and a British
cross-sectional study (1,051 pts). The model is based on
18 health states and 19,000 nodes.
RESULTS: The relative risk of relapse of haloperidol and
olanzapine with respect to sertindole is respectively equal to
1.4 and 1.2. Not only is sertindol self-financing because of
saved hospital admissions (- $12,000 compared with halo-
peridol and -$6,500 compared with olanzapine), but it
produces a slight net savings compared with the two com-
ponents. Olanzapine and haloperidol are dominated strat-
egy with a lower effectiveness and a greater cost. A sensitiv-
ity analysis carried out on toxicity, compliance, relapse, and
drop-out rates confirms the robustness of the results.
CONCLUSION: In schizophrenia, sertindole brings a
benefit of 5 months without relapse compared with olan-
zapine and 13.5 months with respect to haloperidol. In
terms of cost-effectiveness, the study clearly shows the in-
terest of sertindole.
COMPARISON OF STANDARD GAMBLE,
TIME TRADE-OFF, AND VISUAL ANALOG
SCALE SCORES FOR HYPOTHETICAL
STROKE HEALTH STATES USING A
COMPUTER-BASED PROGRAM
Namjoshi MA, Taylor TN
University of Iowa, Iowa City, lA, USA
The most frequently used techniques for conducting util-
ity assessments are the Standard Gamble (SG), the Time
Trade-Off (TTO), and the Visual Analog Scale (VAS).
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OBJECTIVES: The objectives of this study were to com-
pare scores obtained on the SG, TIO, and VAS for hypo-
thetical stroke health states; to determine the effect of age
and gender on utility scores; to identify any ceiling or
floor effects, and to determine the presence of interviewer
effects.
METHODS: Forty-nine PharmD students from the Col-
lege of Pharmacy at the University of Iowa were selected
as the sample, and utility assessments were conducted by
two interviewers, for hypothetical stroke scenarios adapted
from the Glasgow Outcomes Scale. The health states
evaluated were Good Recovery, Moderate Disability, Se-
vere Disability, and a Vegetative State. Two rounds of
utility assessments were conducted. The two rounds of
interviews were separated by a period of 4 months. Re-
gression analysis was used to identify the factors influenc-
ing utility scores.
RESULTS: Mean SG scores for the four health states
were 82.2, 62.7, 26.3, and 3.3, respectively. TTO scores
for the four health states were 79.9, 57.3, 24.6, and 2.9,
respectively. However, VAS scores were found to be
higher than both ITO and SG scores. Neither age nor
gender were found to be statistically significant determi-
nants of reported utility scores. Interviewer effects were
found for one out of 12 assessments in round 1, while
none were observed in round 2. Floor effects were ob-
served for all three techniques for the vegetative state.
CONCLUSION: Further research using larger, more rep-
resentative samples from the general population is re-
quired to establish the validity of computer-based pro-
grams for utility assessments.
CHANGES IN SEXUAL FUNCTION AND
BOTHER IN MEN TREATED FOR
PROSTATE CANCER: RESULTS FROM
THE CaPSURETM DATABASE
Flanders 51, Henning JM', Lubeck DP2, Pasta D]',
Stoddard M12, Litwin MS3
'TAP Holdings Inc., Deerfield, IL, USA; 2Technology
Assessment Group, San Francisco, CA, USA; JUniversity of
Califomia at Los Angeles, Department of Urology,
Los Angeles, CA, USA
OBJECTIVE: To determine the effect of treatment choice
radical prostatectomy (RP) with or without nerve sparing
or pelvic irradiation (XRT) on sexual function and sexual
bother after controlling for sociodemographic and clini-
cal factors.
METHODS: We studied 131 men (mean age 64 ::'::: 6.7
yrs) from the CaPSURETM database, a longitudinal pros-
tate cancer registry. Patients had undergone either RP or
XRT and had a minimum of one year of follow-up with
health-related quality of life (HRQOL) information. Co-
variates were age, disease stage, and treatment. Sexual
function and sexual bother were measured with the
UCLA Prostate Cancer Index on 0-100 scales (higher
